Literature DB >> 21150712

Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro.

Mark A DeBenedette1, David M Calderhead, Irina Y Tcherepanova, Charles A Nicolette, Don G Healey.   

Abstract

Electroporation of mature dendritic cells (DC) with RNA-encoding CD40L greatly enhances the production of interleukin (IL)-12, a proinflammatory cytokine necessary for the induction of T-cell immunity. Results presented herein reveal a correlation between the priming of CD28(+) antigen-reactive effector memory cytotoxic T lymphocytes (CTL) displaying 3 or 4 simultaneous effector functions and the quantity of IL-12 produced by postmaturation electroporation-CD40L DC. By using multiparameter flow cytometry, the quantities of IL-12 needed to prime naive antigen-reactive T cells to simultaneously produce interferon-γ and tumor necrosis factor-α in the presence or absence of IL-2 secretion in conjunction with lytic activity defined by CD107a expression can be used to determine the overall potency of a DC product. In the presence of IL-12, CTL differentiation toward lytic function is not accompanied by a reduction in the secretion of interferon-γ and tumor necrosis factor-α. Therefore, by measuring the availability of IL-12 one can predict the potency of a DC immunotherapeutics in relation to its ability to drive distinct effector memory CTL subsets with multifunctional activities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21150712     DOI: 10.1097/CJI.0b013e3181fb651a

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  15 in total

Review 1.  In situ dendritic cell vaccination for the treatment of glioma and literature review.

Authors:  Ming Li; Shuangyin Han; Xiwen Shi
Journal:  Tumour Biol       Date:  2015-08-29

2.  Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

Authors:  Cynthia L Gay; Mark A DeBenedette; Irina Y Tcherepanova; Alicia Gamble; Whitney E Lewis; Anna B Cope; JoAnn D Kuruc; Kara S McGee; Mary F Kearney; John M Coffin; Nancie M Archin; Charles B Hicks; Joseph J Eron; Charles A Nicolette; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-21       Impact factor: 2.205

3.  Adenovirus co-expressing CD40 ligand and interleukin (IL)-2 contributes to maturation of dendritic cells and production of IL-12.

Authors:  Zhi Guo; Hong-Yan Gao; Tian-Yang Zhang; Jin-Xing Lou; Kai Yang; Xiao-Dong Liu; Xue-Peng He; Hui-Ren Chen
Journal:  Biomed Rep       Date:  2016-10-06

4.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 5.  Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Authors:  Rekha A Kumbla; Robert A Figlin; Edwin M Posadas
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

6.  Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs.

Authors:  Erik Berk; Ravikumar Muthuswamy; Pawel Kalinski
Journal:  Vaccine       Date:  2012-05-01       Impact factor: 3.641

7.  A novel recombinant protein of ephrinA1-PE38/GM-CSF activate dendritic cells vaccine in rats with glioma.

Authors:  Ming Li; Bin Wang; Zhonghua Wu; Jiadong Zhang; Xiwen Shi; Wenlan Cheng; Shuangyin Han
Journal:  Tumour Biol       Date:  2015-02-13

Review 8.  Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Authors:  Susanna A Curtis; Justine V Cohen; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.945

9.  Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs.

Authors:  Erik Berk; Pawel Kalinski
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

10.  A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Cheryl L Chiang; Janos Tanyi; Greg Motz; Klara Balint; Rosemarie Mick; George Coukos
Journal:  J Transl Med       Date:  2013-06-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.